TRIM24 Expression as an Independent Biomarker for Prognosis and Tumor Recurrence in HNSCC

Abstract

Background: Head and neck squamous cell carcinomas (HNSCCs) are among the most common cancers in humans worldwide and have a rather poor prognosis. TRIM24 has various intracellular functions and was identified in other cancer entities as a poor prognostic factor for patients. Methods: The expression of TRIM24 was evaluated by using immunohistochemistry. We used a large and representative cohort of 341 HNSCC patients. Data derived from immunohistochemistry evaluation was correlated with clinicopathological data from HNSCC patients. Results: The TRIM24 expression in HNSCC primary tumors is negatively correlated with the p16 status of the tumor tissues. Primary tumors of patients who developed a local recurrence were significantly more often positive for TRIM24. Kaplan–Meier analyses and Cox regression showed that patients with TRIM24 expressing tumors have significantly worse overall survival and progression-free survival and that TRIM24 expression is independent of other established risk factors. Conclusions: TRIM24 might be a new prognostic biomarker for the survival prognosis and early detection of local recurrences in HNSCC patients. It could be used for risk stratification of HNSCC patients and to identify those patients who are more prone to develop a local recurrence and therefore could profit from more frequent follow-up examinations.

Identifying Predictive Biomarkers for Head and Neck Squamous Cell Carcinoma Response

“…The institutional ethic committee at the University Hospital Rostock approved the study (number A2022-0120), which was conducted in accordance with the Declaration of Helsinki of 1975. An independent, well-described cohort from primary HNSCCs was used as a control group to validate our prognostic findings [26][27][28].…”

Identification of bromodomain-containing proteins prognostic value and expression significance based on a genomic landscape analysis of ovarian serous cystadenocarcinoma

“…SP140 might be a biomarker in head and neck squamous cell carcinoma ( 89 ). TRIM24 is a possible prognostic marker for prostate cancer ( 90 ), head and neck squamous cell carcinomas ( 91 ) and breast cancer ( 92 ). However, whether these indicators can be used as prognostic markers independently for OSC is still unclear.…”

TRIM21 Expression as a Prognostic Biomarker for Progression-Free Survival in HNSCC

“…We analyzed TRIM21 expression in HNSCC specimens derived from a cohort of 419 patients diagnosed between 2012 and 2015 at the Institute of Pathology of the University Medical Center Schleswig-Holstein, Germany, as reported previously [ 13 , 34 , 35 , 36 , 37 , 38 , 39 ]. Tumor samples were derived from PTs, LMs, RTs and DMs.…”

“…To assess the HPV status in the tumor samples, we used the p16 status as a surrogate marker [ 9 ]. Protein expression was detected with immunohistochemical staining using the mouse monoclonal antibody p16 (p16 CINtec ready to use kit, clone E6H4™, Roche Ventana Medical Systems, Tucson, AZ, USA), as described previously [ 18 , 38 ]. Binding was revealed using the Dab system delineated above.…”